Rotigaptide in Endothelial Dysfunction?
Not Applicable
Completed
- Conditions
- Ischaemic Heart Diseases
- Registration Number
- NCT07192744
- Lead Sponsor
- University of Edinburgh
- Brief Summary
Arterial occlusion can lead to tissue ischemia and, if prolonged, end organ infarction. Clinical and experimental data would suggest that restoration of blood flow might trigger additional injury beyond that induced by the ischemia alone, so called Ischemia Reperfusion (IR) injury. IR injury impairs endothelial function through a mechanism that may involve intercellular gap junctions. Rotigaptide (ZP-123) is an anti-arrhythmic drug promoting intercellular coupling by increasing gap junction conductance. We intend to test the hypothesis that rotigaptide protects the forearm arterial circulation from IR-induced endothelial dysfunction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
- healthy males between 18-65 years of ages, non-smokers.
Exclusion Criteria
- Any concurrent illness or chronic medical condition. Concurrent use of vasoactive medication. Smoking history.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Change in forearm blood flow after ischaemia reperfusion with or without co-infusion of Rotigaptide 20 fixed timepoints throughout the study up to 4 hours
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Edinburgh, 49 Little France Crescent
🇬🇧Edinburgh, United Kingdom
University of Edinburgh, 49 Little France Crescent🇬🇧Edinburgh, United Kingdom